SLC5A2 and kidney disorder: Clinical trials have shown that sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the progression of kidney disease in type 2 diabetic patients at high cardiovascular risk with preserved renal function [10–12] or with different degrees of renal impairment, regardless of baseline renal function [13, 14].